Cequent, which was acquired by Marina Biotech in 2010, developed new, clinically compatible therapies based on RNA interference (RNAi) therapies. The company focused its efforts on the pre-clinical development of products to treat gastrointestinal diseases, including familial polyposis, inflammatory bowel disease and colon cancer.